Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.71 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.71 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.55 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.55 |
| ▸ | AGXT | P21549 | 1/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.52 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | HTR7 | P34969 | 1/20 | 0.47 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.46 |
| ▸ | DCLRE1B | Q9H816 | 1/20 | 0.44 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.44 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfur Dioxide SCHEMBL29045638 | 0.91 | TAAR1 (0.61) | TAAR1ESR2CYP11B2CYP3A4CYP17A1 | |
| SCHEMBL15605009 | 0.90 | TAAR1 (0.71) | TAAR1ESR2CYP11B2CYP3A4CYP17A1 | |
| SCHEMBL26821707 | 0.89 | TAAR1 (0.56) | TAAR1ESR2CYP3A4AGXTHTR1A | |
| SCHEMBL28269989 | 0.89 | TAAR1 (0.56) | TAAR1ESR2CYP3A4AGXTHTR1A | |
| SCHEMBL198702 | 0.89 | TAAR1 (0.68) | TAAR1ESR2CYP11B2CYP3A4CYP17A1 | |
| Biphenyl SCHEMBL25183774 | 0.86 | TAAR1 (0.67) | TAAR1ESR2CYP11B2CYP3A4CYP17A1 | |
| SCHEMBL29451178 | 0.86 | TAAR1 (0.67) | TAAR1ESR2CYP11B2CYP3A4CYP17A1 | |
| SCHEMBL200605 | 0.86 | TAAR1 (0.67) | TAAR1ESR2CYP11B2CYP3A4CYP17A1 | |
| SCHEMBL16605626 | 0.86 | TAAR1 (0.65) | TAAR1ESR2CYP11B2CYP3A4CYP17A1 | |
| SCHEMBL16605628 | 0.86 | TAAR1 (0.65) | TAAR1ESR2CYP11B2CYP3A4CYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4695240-A2 | CYCLIC VINYL SULFONE WRN INHIBITORS | Nimbus Wadjet, Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| WO-2024215923-A2 | CYCLIC VINYL SULFONE WRN INHIBITORS | NIMBUS WADJET, INC. (US) | 2024-10-17 | — | — | WO | disclosed |
| US-12100809-B2 | Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2024-09-24 | — | — | US | disclosed |
| WO-2024014851-A1 | NOVEL PURINE DERIVATIVE COMPOUNDS AS HIF-1 PROTEIN INHIBITOR | 주식회사 넥스트젠바이오사이언스 | 2024-01-18 | — | — | WO | disclosed |
| US-20230322725-A1 | INHIBITORS FOR THE B-CATENIN/B-CELL LYMPHOMA 9 (BCL9) PROTEIN-PROTEIN INTERACTION | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2023-10-12 | — | — | US | disclosed |
| CN-115557913-A | Benzoazaheterocyclic compounds and application thereof in medicines | 广东东阳光药业有限公司 | 2023-01-03 | — | — | CN | disclosed |
| CN-114761000-A | Substituted 1, 6-naphthyridine inhibitors of CDK5 | 金翅雀生物公司 | 2022-07-15 | — | — | CN | disclosed |
| US-20220149436-A1 | NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2022-05-12 | — | — | US | disclosed |
| US-11283107-B2 | Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2022-03-22 | — | — | US | disclosed |
| EP-3621141-A1 | NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2020-03-11 | — | — | EP | disclosed |
| US-20090325065-A1 | NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2009-12-31 | — | — | US | disclosed |
| US-7623214-B2 | Liquid crystal materials | DOW CORNING CORPORATION (US) | 2009-11-24 | — | — | US | disclosed |
| EP-1713880-B1 | LIQUID CRYSTAL MATERIALS | DOW CORNING (US) | 2009-10-28 | — | — | EP | disclosed |
| CN-101432923-A | Nonaqueous electrolyte solution and nonaqueous electrolyte secondary battery | MITSUBISHI CHEM CORP (JP) | 2009-05-13 | — | — | CN | disclosed |
| US-20090115957-A1 | Liquid crystal materials | DOW SILICONES CORPORATION | 2009-05-07 | — | — | US | disclosed |
| EP-2012386-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS ELECTROLYTE SECONDARY BATTERY | Mitsubishi Chemical Corporation (JP) | 2009-01-07 | — | — | EP | disclosed |
| EP-1713880-A1 | LIQUID CRYSTAL MATERIALS | Dow Corning Corporation (US) | 2006-10-25 | — | — | EP | disclosed |
| WO-2005075603-A1 | LIQUID CRYSTAL MATERIALS | DOW CORNING CORPORATION (US) | 2005-08-18 | — | — | WO | disclosed |
| US-6242654-B1 | REACTING A PHENOLATE COMPOUND WITH AN ORGANIC FLUORINATING AGENT TO PREPARE A FLUORINE SUBSTITUTED AROMATIC COMPOUND | MITSUI CHEMICALS, INC. (JP) | 2001-06-05 | — | — | US | disclosed |
| EP-1013629-A1 | Preparation process of fluorine subsituted aromatic compound | Mitsui Chemicals, Inc. (JP) | 2000-06-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322725-A1 | INHIBITORS FOR THE B-CATENIN/B-CELL LYMPHOMA 9 (BCL9) PROTEIN-PROTEIN INTERACTION | BCL9, BCL9L, BCL3 | TAAR1 4863/4885ESR2 1703/4885CYP11B2 3220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.